Xiamen Amoytop Biotech Co., Ltd. (SHA:688278)

Market Cap	29.74B
Revenue (ttm)	2.95B
Net Income (ttm)	880.92M
Shares Out	406.80M
EPS (ttm)	2.16
PE Ratio	33.88
Forward PE	25.24
Dividend	0.62 (0.85%)
Ex-Dividend Date	May 9, 2025

Volume	1,365,641
Average Volume	2,722,698
Open	73.01
Previous Close	73.11
Day's Range	72.70 - 73.39
52-Week Range	46.30 - 88.38
Beta	0.09
RSI	39.99
Earnings Date	Aug 22, 2025

About Xiamen Amoytop Biotech

Xiamen Amoytop Biotech Co., Ltd. engages in research, development, production, and sale of recombinant protein drugs in China. The company provides solutions for diseases, such as viral hepatitis, malignant tumors, and immunotherapy. Xiamen Amoytop Biotech Co., Ltd. was founded in 1996 and is based in Xiamen, China.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1996
• Employees: 2,423
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688278

Financial Performance

In 2024, Xiamen Amoytop Biotech's revenue was 2.82 billion, an increase of 34.13% compared to the previous year's 2.10 billion. Earnings were 827.60 million, an increase of 49.00%.